Flight Centre Travel Group Ltd (ASX: FLT) shares are taking a hit on Wednesday after the travel company released its FY26 results.

At the time of writing, the Flight Centre share price is down 6.79% to $12.08.

The reaction is probably not what shareholders were hoping for, especially with a few solid numbers in the result.

But once you dig a little deeper, there are also some weaker spots that help explain why the market has reacted this way.

Let’s take a closer look at the numbers.

FY26 results were mixed

Flight Centre reported record total transaction value (TTV) of $25.7 billion, up 4.7% from FY25, while revenue increased 2.5% to $2.9 billion.

Underlying EBITDA also moved higher, rising 3.9% to $466 million. However, underlying profit before tax went the other way, falling 4% to $278 million.

Statutory net profit after tax (NPAT) increased 38% to $149 million, while earnings per share (EPS) jumped 43% to 70.9 cents.

Shareholders also received some good news on the dividend front, with Flight Centre declaring a fully franked final dividend of 30 cents per share. This takes the full-year payout to 42 cents, up 5% on FY25.

The company said trading was strong through the first 9 months before conflict in the Middle East disrupted travel during the fourth quarter.

Flight Centre estimates the disruption cost its leisure business around $60 million in profit.

Why are Flight Centre shares falling?

The weaker result from Flight Centre’s leisure business looks to be one of the biggest reasons investors are selling the shares today.

Barrenjoey analyst Matt Ryan said underlying profit before tax came in around 2% below market expectations, while the leisure division missed consensus by about 8%.

There was still growth in travel volumes, with leisure TTV rising 7.4% to $12.6 billion. But that didn’t flow through to earnings, with underlying EBITDA falling 6.7% to $250 million and underlying profit before tax dropping 21.7% to $139 million.

The corporate business had a stronger year, with underlying profit before tax rising 28% to $240 million.

Furthermore, there’s also a few reasons for investors to be cautious heading into FY27.

Flight Centre expects corporate earnings to be more heavily weighted toward the second-half, with first-half profit likely to come in below last year.

Flight Centre pointed to the Middle East war, upfront investment, currency movements and contract timing as reasons for the softer start.

What happens next?

Despite the subdued mood, there are still a few positive signs heading into FY27.

Flight Centre said July delivered record TTV and its strongest July leisure profit since 2015.

Long-haul travel from Australia is also starting to improve, which could help the business over the year ahead.

RBC Capital Markets highlighted the strong July performance, although there’s still some uncertainty around how quickly earnings can recover.

Investors should get a better idea in November, when Flight Centre plans to provide its FY27 earnings guidance at its AGM.

The post Flight Centre shares are sinking 7% after its FY26 results. Here’s why appeared first on The Motley Fool Australia.

More reading

• Flight Centre Travel Group delivers record year despite Q4 challenges
• These are the 10 most shorted ASX shares
• 3 top ASX dividend shares to buy now
• Where to invest $5,000 in Australian shares now
• These are the 10 most shorted ASX shares

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Flight Centre Travel Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The IVE Group Ltd (ASX: IGL) share price is in focus today after the company delivered a full-year FY26 result in line with guidance. The company raised its dividend above guidance to 18.5 cents per share and reported improved margins, despite softer revenue in challenging market conditions.

What did IVE Group report?

• Revenue fell 1.8% to $937.4 million from $954.8 million in FY25.
• Pre-AASB 16 underlying NPAT increased 3.0% to $52.5 million.
• Post-AASB 16 underlying NPAT slipped 1.7% to $51.2 million.
• IFRS NPAT dropped to $37.4 million from $46.7 million a year ago.
• Final fully franked dividend lifted to 9.0 cents per share, resulting in a full-year dividend of 18.5 cents per share, topping guidance.
• Net debt was $173.2 million, up from $114.4 million, reflecting recent acquisitions and investments in capacity.

What else do investors need to know?

IVE Group continued to roll out its 2030 strategy during the year, integrating three new acquisitions—Impressu, Daily Press, and BMS. The group moved five business units to its new Kemps Creek supersite and opened a NSW packaging plant, aiming to unlock operational efficiencies and expansion opportunities.

The company also focused on commercialising artificial intelligence, combining in-house platforms and strategic partnerships to drive recurring revenue and productivity. Additionally, its third-party logistics footprint grew with a new facility in Dandenong and significant client wins.

What did IVE Group management say?

Managing Director Matt Aitken said:

IVE delivered on guidance with a solid full-year performance underpinned by continued margin resilience, despite an increasingly difficult economic landscape. Over the past year the Group has made good progress against our 2030 strategy including the move to the new Dandenong 3PL site, the relocation of five business units to the Kemps Creek supersite and a number of scale enhancing and/or strategic acquisitions together which provide additional opportunities for operational efficiencies and long-term revenue growth.

What’s next for IVE Group?

Looking ahead to FY27, management expects underlying NPAT before lease accounting impacts to remain broadly stable. Capital expenditure is set to fall sharply to about $26 million as major fit-outs and capacity expansions wrap up.

IVE Group plans to keep net debt below 1.5 times pre-AASB 16 EBITDA, and will return to a dividend payout ratio of 55–65% of underlying earnings. Board renewal will see four directors retire over two years, supporting further evolution as IVE pursues its long-term growth strategy.

IVE Group share price snapshot

Over the past 12 months, IVE Group shares have declined 3%, trailing the All Ordinaries Index (ASX: XAO), which has risen 2% over the same period.

View Original Announcement

The post IVE Group posts FY26 result, beats dividend guidance appeared first on The Motley Fool Australia.

More reading

• Capricorn Metals completes Big Springs divestment, sharpens gold focus
• South32, Woolworths, BHP shares reach 52-week high: Buy, sell or hold?
• Corporate Travel Management secures new funding and updates on FY25 and FY26 earnings
• L1 Gold Fund raises $254.9m in placement and entitlement offers
• Flight Centre shares are sinking 7% after its FY26 results. Here’s why

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Starpharma Holdings Ltd (ASX: SPL) share price is in focus today as the company reported a 145% jump in full-year revenue to $12 million and reduced its reported loss by 25% to $7.5 million.

What did Starpharma report?

• Revenue rose 145% to $12.0 million (FY25: $4.9 million), mainly from the Genentech licence agreement.
• Reported loss improved to $7.5 million, down from $10.0 million last year.
• Closed FY26 with $11.0 million in cash; post-year-end capital raising added $30 million to strengthen funding.
• Research and product development spending was $11.1 million (FY25: $8.4 million), after R&D tax incentive.

What else do investors need to know?

Starpharma strengthened its balance sheet after the reporting period, raising $30 million through a well-supported entitlement offer. This extends its funding runway into FY28, giving the company greater flexibility to advance its pipeline programs.

The company has continued to invest in its DEP® technology, with particular progress on its lead radiopharmaceutical asset, DEP® HER2-Lutetium, and next-generation oncology candidates. New and existing strategic partnerships further reinforce its commercial and research initiatives.

What did Starpharma management say?

Chief Executive Officer Cheryl Maley said:

During FY26, we significantly advanced our lead radiopharmaceutical asset, DEP® HER2-Lutetium, executed new strategic partnerships and strengthened existing ones, and further validated the broad potential of DEP® with a focus on targeted oncology treatments. We thank our shareholders for their continued support throughout the year. Our focus remains on building long-term shareholder value through the development of a pipeline of targeted oncology therapies enabled by our DEP® technology. The team is committed to executing on the milestones ahead and translating our scientific and commercial progress into meaningful outcomes for patients and shareholders.

What’s next for Starpharma?

Looking ahead, Starpharma is focused on advancing its clinical and preclinical DEP® pipeline, including further development of the DEP® HER2-Lutetium asset in targeted oncology. Management says the recently strengthened cash position supports the group’s research programs and continued progress of its key partnerships.

The company aims to deliver long-term value for shareholders by progressing its innovative dendrimer-based therapies, with a particular emphasis on expanding its presence in oncology and strengthening its commercial relationships.

Starpharma share price snapshot

Over the past 12 months, Starpharma shares have surged more than 500%, significantly outpacing the All Ordinaries Index (ASX: XAO).

View Original Announcement

The post Starpharma: FY26 earnings reveal strong revenue growth and improved loss appeared first on The Motley Fool Australia.

More reading

• Arena REIT faces leasing challenge after Edge Early Learning enters administration
• DUG Technology scores US$9.3m software and HPC contract
• Down 56%: Has the market lost interest in Life360 shares?
• Inflation falls again, but could the RBA still raise interest rates?
• 3 reasons I’d buy the NDQ ETF now

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.